CLINICAL PROFILE AND THE OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY: A SINGLE CENTRE EXPERIENCE

AFAQ AHMAD KHAN; RESHMA ROSHAN; NISAR AHMAD KHAN; SANTOSH GOVIND RATHOD; SAJAD AHMED GEELANI; JAVID RASOOL BHAT

doi:10.22159/ajpcr.2022.v15i3.44087

Authors

AFAQ AHMAD KHAN Department of Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
RESHMA ROSHAN Department of Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
NISAR AHMAD KHAN Department of Medicine, Government Medical College, Baramulla, Jammu and Kashmir, India.
SANTOSH GOVIND RATHOD Department of Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
SAJAD AHMED GEELANI Department of Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.
JAVID RASOOL BHAT Department of Clinical Hematology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i3.44087

Keywords:

Hematological malignancy, COVID-19, Case fatality

Abstract

Objective: In the present study, we are reporting the clinical profile; and outcomes of COVID-19 in patients with hematological malignancy at tertiary care hospitals.

Methods: Data from laboratory-confirmed 40 COVID-19 patients diagnosed between January 1, 2021 and July 31, 2021, were analyzed retrospectively. All COVID-19 patients with hematological malignancy (n=40) were included in the study.

Results: In the present study, a total of 40 patients were included. Of 40, 25 (62.5%) were males, and 15 (37.5%) were females. The median age in this study was 43 years (Range, 8–70). Of these 40 patients, acute myeloid leukemia was the most common malignancy 11 (27.5%), followed by acute lymphoblastic leukemia 9 (22.5%) than non-Hodgkin lymphoma 5 (12.5%), plasma cell dyscrasia 4 (10%), chronic myeloid leukemia 4 (10%), chronic lymphocytic leukemia 3 (7.5%), acute promyelocytic leukemia 2 (5%), chronic myelomonocytic leukemia 2 (5%). Mean hemoglobin was (8.04 g/dl), white blood cell count was (10.14×109/l), platelet count was (77.7×109/l) creatinine was (0.86 mg/dl), bilirubin was (1.24 mg/dl). The overall case-fatality rate was 8 (22.5%).

Conclusion: Patients with hematological malignancy are immunocompromised, and our study reveals that there is an increased case fatality rate among these patients. Hence, physicians should be aggressive in the management of COVID‐19 patients with hematological malignancy.

Downloads

Download data is not yet available.

References

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199-207.

Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and Coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer 2020;139:43-50.

Poortmans PM, Guarneri V, Cardoso MJ. Cancer and COVID-19: What do we really know? Lancet 2020;395:1884-5.

Infante MS, González-Gascón Y Marín I, Muñoz-Novas C, Churruca J, Foncillas MÁ, et al. COVID-19 in patients with hematological malignancies: A retrospective case series. Int J Lab Hematol 2020;42:e256-9.

Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna- Villaorduna A, et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital system. Cancer Discov 2020;10:935-41.

Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, et al. Survival study of hospitalized patients with concurrent COVID-19 and hematological malignancies. Br J Haematol 2020;190:e16-20.

Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, et al. Clinical outcome of coronavirus disease 2019 in haemato-oncology patients. Br J Haematol 2020;190:e64-7.

Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol 2020;92:2067-73.

Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, et al. The outcome of COVID-19 in patients with hematological malignancy. J Med Virol 2021;93:1099-104.

Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood 2020;136:2881-92.

Ramaswamy A, Nayak L, Moulik NR, Sengar M, Chinnaswamy G, Jobanputra K, et al. COVID-19 in cancer patients on active systemic therapy-outcomes from LMIC scenario with an emphasis on the need for active treatment. Cancer Med 2020;9:8747-53.

Singh S, Singh J, Paul D, Jain K. Treatment of acute leukemia during COVID-19: Focused review of evidence. Clin Lymphoma Myeloma Leuk 2021;21:289-94.